rexulti Drug Patent Profile

When do Rexulti patents expire, and what generic alternatives are available?

Rexulti is a drug marketed by Otsuka and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-seven patent family members in thirty-nine countries.

The generic ingredient in REXULTI is brexpiprazole. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the brexpiprazole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rexulti

A generic version of rexulti was approved as brexpiprazole by ALEMBIC on January 13^th, 2025.

Summary for rexulti

International Patents:	77
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	11
Patent Applications:	945
Drug Prices:	Drug price information for rexulti
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for rexulti
What excipients (inactive ingredients) are in rexulti?	rexulti excipients list
DailyMed Link:	rexulti at DailyMed

See drug prices for rexulti

Recent Clinical Trials for rexulti

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Unity Health Toronto	Phase 4
McMaster University	Phase 4
University Health Network, Toronto	Phase 4

See all rexulti clinical trials

Pharmacology for rexulti

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for REXULTI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
REXULTI	Tablets	brexpiprazole	4 mg	205422	16	2019-07-10

US Patents and Regulatory Information for rexulti

rexulti is protected by six US patents and five FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-004	Jul 10, 2015	AB	RX	Yes	Yes
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-003	Jul 10, 2015	AB	RX	Yes	No
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-005	Jul 10, 2015	AB	RX	Yes	No	RE48059*PED				Y
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-006	Jul 10, 2015	AB	RX	Yes	No	RE48059*PED				Y
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-005	Jul 10, 2015	AB	RX	Yes	No	9,839,637*PED				Y
Otsuka	REXULTI	brexpiprazole	TABLET;ORAL	205422-005	Jul 10, 2015	AB	RX	Yes	No	10,307,419*PED				Y

EU/EMA Drug Approvals for rexulti

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Otsuka Pharmaceutical Netherlands B.V.	Rxulti	brexpiprazole	EMEA/H/C/003841Treatment of schizophrenia.	Authorised	no	no	no	2018-07-26

International Patents for rexulti

When does loss-of-exclusivity occur for rexulti?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Hungary

India

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

New Zealand

Philippines

Poland

Portugal

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering rexulti around the world.

Country	Patent Number	Title	Estimated Expiration
South Africa	201402333
Canada	2851588
Slovenia	2767285
New Zealand	622639
South Korea	20140075754
Mexico	376092

Supplementary Protection Certificates for rexulti

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1869025	32/2018	Austria		PRODUCT NAME: BREXPIPRAZOL ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/18/1294 (MITTEILUNG) 20180727
1869025	LUC00086	Luxembourg		PRODUCT NAME: BREXPIPRAZOLE OU UN SEL DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1294 20180730
1869025	SPC/GB18/038	United Kingdom		PRODUCT NAME: BREXPIPRAZOLE OR A SALT THEREOF; REGISTERED: UK EU/1/18/1294/001(NI) 20180730; UK PLGB 506970019 20180730; UK PLGB 506970020 20180730; UK PLGB 506970021 20180730; UK PLGB 506970022 20180730; UK PLGB 506970023 20180730; UK EU/1/18/1294/007(NI) 20180730; UK EU/1/18/1294/008(NI) 20180730; UK EU/1/18/1294/009(NI) 20180730; UK EU/1/18/1294/010(NI) 20180730; UK EU/1/18/1294/011(NI) 20180730; UK PLGB 506970024 20180730; UK EU/1/18/1294/002(NI) 20180730; UK EU/1/18/1294/003(NI) 20180730; UK EU/1/18/1294/004(NI) 20180730; UK EU/1/18/1294/005(NI) 20180730; UK EU/1/18/1294/006(NI) 20180730
1869025	C01869025/01	Switzerland		PRODUCT NAME: BREXPIPRAZOL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66475 17.07.2018
1869025	18C0004	France		PRODUCT NAME: BREXPIPRAZOLE OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/18/1294 20180730
1869025	2018/034	Ireland		PRODUCT NAME: BREXPIPRAZOLE OR A SALT THEREOF; NAT REGISTRATION NO/DATE: EU/1/18/1294 20180726; FIRST REGISTRATION NO/DATE: JOURNAL OF THE INTELLECTUAL PROPERTY OFFICE OF IRELAND (NO. 2402)

REXULTI (brexpiprazole) market dynamics and financial trajectory: sales trends, competitive pressure, and exclusivity risk

Last updated: June 3, 2026

REXULTI (brexpiprazole) revenue has been steady but pressured by slower growth, channel normalization, and intensified competition in schizophrenia and MDD adjunctive therapy. The drug’s commercial trajectory depends on (1) US payer access and formulary position versus aripiprazole and other atypical antipsychotics, (2) treatment persistence in schizophrenia and major depressive disorder (MDD) adjunct, and (3) patent and regulatory timelines governing US generics and potential “authorized” or non-authorized erosion. Near-term value risk sits in the combination of limited label expansion upside and rising generic/program-level substitution in branded CNS categories.

What is REXULTI (brexpiprazole) revenue trend and financial trajectory by geography?

Answer: REXULTI has functionally matured as a mid-size branded CNS asset. It does not show the explosive uptake profile of early blockbuster CNS launches, and the commercial curve is shaped more by retention and payer mix than by rapid market expansion.

US commercialization dynamics that typically drive REXULTI’s trajectory

REXULTI’s market performance in the US is driven by:

• Class switching risk: Antipsychotic choice in schizophrenia frequently consolidates around cost and formulary tier placement, especially where payers prefer lower net-cost alternatives.
• Adjunctive depression churn: For MDD adjunct, persistence is sensitive to efficacy response, side-effect tolerability, and prescriber comfort with alternative augmentation strategies.
• Net pricing reality: Branded CNS sales reflect discounting, contracting, and rebating effects. Reported “gross-to-net” compression is a key driver of net sales trajectory in mature CNS portfolios.

International economics

International sales tend to track:

• Local reimbursement categories for schizophrenia and depressive disorders,
• Formulary penetration under national health systems and private pay tiers,
• Competitor density within each country’s atypical antipsychotic lineup.

How do schizophrenia and MDD adjunct demand dynamics shape REXULTI sales?

Answer: Demand is split between chronic schizophrenia maintenance and time-limited MDD adjunct continuation, with different churn drivers.

Schizophrenia maintenance: stability with slow payer-driven substitution

• Therapy intent: Long-term maintenance creates stickiness at the prescriber and patient level.
• Erosion mechanics: The main erosion channel is payer formulary movement and net-cost dynamics rather than immediate loss of clinical adherence.
• Switch triggers: Akathisia, weight gain, metabolic profile, tolerability, and long-term safety perceptions shape switching to other atypicals.

MDD adjunct: response-dependent utilization

• Higher volatility: MDD adjunct utilization is more sensitive to individual response and early discontinuation.
• Competitive overlap: Brexpiprazole competes against multiple augmentation options across payer preference frameworks, including other branded and generic CNS agents depending on local economics.

What market factors determine REXULTI’s competitive landscape versus aripiprazole and other atypicals?

Answer: Net cost, formulary status, and prescriber habit dominate. Clinical nuance matters but typically does not prevent substitution when payers tighten controls.

Direct competition themes

• Aripiprazole-based replacement risk: Aripiprazole’s generic availability and entrenched clinical use create a low-cost benchmark for payers.
• Alternative atypicals: Cariprazine, quetiapine, olanzapine, and risperidone form overlapping choice sets depending on dosing schedules, side-effect profile, and guideline preference patterns.
• Managed care levers: Step therapy, prior authorization, and formulary tiers are the main commercial levers affecting branded atypical access.

Competitive positioning: what matters to buyers

For payers and pharmacy benefit managers, brexpiprazole competes as a:

• Mid-to-lower net-cost branded option only if pricing contracts maintain payer acceptance,
• Formulary alternative where a prescriber’s starting choice locks in for months via persistence.

When does REXULTI lose exclusivity in the US, and what does that mean for generic launch risk?

Answer: Exclusivity loss timing and patent cliffs determine the switch from branded retention to generic price competition. For CNS assets, generic erosion often starts with Paragraph IV or other patent-waiver pathways, then accelerates once multiple barriers fall.

Key exclusivity and patent risk mechanics

REXULTI’s generic-risk profile depends on:

• Whether core composition-of-matter patents remain unexpired at the time of potential FDA ANDA acceptance,
• Whether formulation or method-of-use patents create additional injunction leverage,
• Whether data exclusivity or regulatory exclusivity delays generic approvals independently of patents.

Generic entry scenarios that typically impact sales

• Single barrier fall scenario: One patent expires, but remaining patents continue to deter entry or delay launch.
• Multi-patent cascade: Multiple expirations cluster, enabling faster erosion.
• Settlement-driven launch: A patent settlement can set an agreed launch date even if litigation might have continued.

What patents protect REXULTI (brexpiprazole), and how strong is the patent estate?

Answer: The practical strength of the patent estate is defined by which patents remain enforceable in the US at the time of generic application and whether multiple independent barriers exist. For mid-size branded CNS drugs, the estate is often a patchwork of composition, formulation, and use claims that create a staggered defense path.

Patent estate evaluation framework used for commercial impact

A business-grade assessment should map:

• Core composition patents (highest injunction leverage),
• Formulation and polymorph patents (barrier to “same drug” substitution if claims are specific),
• Method-of-use patents (barrier to label-scoped generic marketing or narrow carve-outs),
• Manufacturing process patents (less common as a barrier in practical generic substitution unless strictly tied to scalable processes).

What this means for erosion velocity

A strong estate typically produces:

• Slower price compression because launch is delayed,
• Lower number of authorized/non-authorized entrants if settlements occur early,
• More leverage for brand for life-cycle extensions, including controlled releases or line-extension formulations where applicable.

What is the Orange Book status of REXULTI, and how many drug listings matter for biosafety or ANDA?

Answer: Orange Book listings function as the map of patent barriers tied to each approved NDA strength and dosage form. For brexpiprazole, the number of active listings and their expiration dates determine practical timing for ANDA challenges.

How to interpret Orange Book listings for commercial risk

• Number of listed patents tied to the NDA matters because each can independently support an injunction.
• Earliest expiration date indicates the first potential generic entry window.
• Patent scope breadth indicates whether a generic can route around by design choices.

Have there been Paragraph IV challenges to REXULTI patents, and what settlements changed launch timing?

Answer: The presence and outcomes of Paragraph IV filings determine the first credible generic launch risk and can shift launch dates via settlements. Paragraph IV litigation also determines whether multiple ANDAs proceed or get consolidated into a single commercial threat.

Why Paragraph IV outcomes drive revenue trajectories

• If the brand wins: erosion is deferred, and PBM contracting may remain stable.
• If the brand settles early: an agreed date creates a predictable erosion timeline.
• If generics win: immediate launch compresses net sales and forces formulary reclassification.

Litigation implications for investors and licensors

• Settlement terms (launch date, market carve-outs, exclusivity triggers) determine how quickly net sales fall.
• Design-around feasibility affects whether a generic can enter without switching costs.

What FDA regulatory milestones apply to REXULTI, including label scope and new indications?

Answer: REXULTI’s financial sensitivity is tied to whether label expansion increases addressable population faster than competitive replacement. In CNS, label additions matter if they produce measurable incremental prescribing and if payers cover the expanded use.

How FDA label scope affects market sizing

• Schizophrenia indications drive a stable base.
• MDD adjunct creates overlap with multiple treatment lines where payer and prescriber decisions can shift quickly.

How does REXULTI compare with cariprazine, quetiapine, and other atypicals on market positioning?

Answer: REXULTI competes in an atypical antipsychotic ecosystem where differentiation is often expressed through tolerability and guideline alignment, but commercial outcomes hinge on net price and formulary adoption.

Competitive comparison dimensions that move sales

• Formulary tier placement in schizophrenia and MDD adjunct,
• Dosing convenience and switching friction,
• Adverse event profile and patient-specific risk,
• PBM contracting and rebates.

What manufacturing and formulation/IP barriers could slow generic substitution for REXULTI?

Answer: Barriers typically come from enforceable formulation patents or specific manufacturing methods tied to approved drug product. Where those exist and remain unexpired, they can delay launch even if core composition claims are weaker.

Practical substitution barriers in branded CNS

• Bioequivalence feasibility: While generics generally clear BE requirements, formulation-specific claims can constrain “identical” approaches.
• Process-specific claims: If process patents exist, generic development may face non-trivial design-around.

What are the commercial implications of patent expiry for REXULTI pricing and net sales?

Answer: Post-expiry, REXULTI net sales typically decline faster than gross retail visibility suggests, driven by PBM switching, rebate renegotiation, and increased dispensing of cheaper alternatives.

Typical post-cliff sales pathway in CNS

• Pre-expiry months: PBMs may begin preemptive tiering.
• Launch month: increased generic dispensing plus competitor promotion.
• Following quarters: rebate compression and switching hardening across plans.

Key Takeaways

• REXULTI’s financial trajectory reflects a mature CNS profile: incremental growth is constrained; persistence and payer mix dominate outcomes.
• Competitive pressure is structural: generic aripiprazole and other atypicals set pricing anchors, increasing substitution incentives.
• Exclusivity timelines drive the inflection: generic entry velocity hinges on Orange Book-listed patents, Paragraph IV outcomes, and any settlement-based launch dates.
• Patent strength matters as a portfolio: composition, formulation, and method-of-use patents collectively determine how fast sales erosion accelerates after the first barrier falls.
• Regulatory label scope affects addressable demand: MDD adjunct volatility changes utilization patterns, but competitive replacement can cap upside.

FAQs

1. How does formulary placement for schizophrenia atypical antipsychotics change REXULTI net sales after generic launches?
2. What Paragraph IV events typically trigger first credible generic entry for branded CNS drugs like REXULTI?
3. How do patent settlements in CNS cases influence negotiated launch dates and market carve-outs?
4. Which Orange Book listing types (composition, formulation, method-of-use) most often delay ANDA launches for brexpiprazole?
5. How do MDD adjunct discontinuation and persistence rates affect branded antipsychotic revenue compared with schizophrenia maintenance?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Center for Drug Evaluation and Research (CDER).
2. FDA Drug Approval Packages and labeling for REXULTI (brexpiprazole). CDER.
3. FDA guidance on ANDA submissions and bioequivalence requirements (where applicable). CDER.

DrugChatter Q&A for REXULTI

Does Rexulti help with treatment-resistant depression?
Rexulti patent expiration date?
Rexulti generic release date?
When will generic rexulti be available?
When will rexulti be generic?